Իսրայել - եբրայերեն - Ministry of Health

bioavenir ltd, israel - entecavir as monohydrate - טבליות מצופות פילם - entecavir as monohydrate 0.5 mg - entecavir

Իսրայել - եբրայերեն - Ministry of Health

bioavenir ltd, israel - entecavir as monohydrate - טבליות מצופות פילם - entecavir as monohydrate 1 mg - entecavir

Իսրայել - եբրայերեն - Ministry of Health

reckitt benckiser (near east) ltd - ibuprofen - תרחיף - ibuprofen 20 mg/ml - ibuprofen - ibuprofen - for the reduction of fever and relief of mild to moderate pain. for infants and children aged 3 months to 12 years (i.e. weighing about 40 kg).

Իսրայել - եբրայերեն - Ministry of Health

reckitt benckiser (near east) ltd - ibuprofen - תרחיף - ibuprofen 20 mg/ml - ibuprofen - ibuprofen - for the reduction of fever and relief of mild to moderate pain. for infants and children aged 3 months to 12 years (i.e. weighing about 40 kg).

Իսրայել - եբրայերեն - Ministry of Health

pharma shalom - aluminium oxide hydrated; dimethicone; magnesium hydroxide - טבליות לעיסות - magnesium hydroxide 200 mg; dimethicone 25 mg; aluminium oxide hydrated 200 mg - combinations

Իսրայել - եբրայերեն - Ministry of Health

pharma shalom - aluminium hydroxide; magnesium hydroxide; simethicone - תרחיף - aluminium hydroxide 175 mg / 5 ml; magnesium hydroxide 200 mg / 5 ml; simethicone 25 mg / 5 ml

Իսրայել - եբրայերեն - Ministry of Health

reckitt benckiser (near east) ltd - ibuprofen - ibuprofen 100 mg - ibuprofen

Իսրայել - եբրայերեն - Ministry of Health

teva israel ltd - simvastatin - טבליה - simvastatin 20 mg - simvastatin - simvastatin - coronary heart disease : in patients with coronary heart disease and hypercholesterolemia simvastatin-teva is indicated to: - reduce the risk of total mortality by reducing coronary death - reduce the risk of non-fatal myocardial infarction - reduce the risk for undergoing myocardial revascularization procedures. - reduce the risk of stroke and transient ischemic attacks (tia). hyperlipidemia: simvastatin-teva is indicated as an adjunct to diet to reduce elevated total-c ldl-c apo b and tg and to increase hdl-c in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (frederickson types iia and iib) simvastatin-teva therefore lowers the ldl-c/hdl-c and the total-c/hdl-c ratios. homozygous familial hypercholesterolemia: simvastatin-teva is also indicated as an adjunct to diet and other non-dietary measures in reducing elevated total cholesterol ldl-cholesterol and apolipoprotein b in patients with homozygous familial hypercholesterolemia when response to thes

Իսրայել - եբրայերեն - Ministry of Health

teva israel ltd - simvastatin - טבליה - simvastatin 10 mg - simvastatin - simvastatin - coronary heart disease : in patients with coronary heart disease and hypercholesterolemia simvastatin-teva is indicated to: - reduce the risk of total mortality by reducing coronary death - reduce the risk of non-fatal myocardial infarction - reduce the risk for undergoing myocardial revascularization procedures.- reduce the risk of stroke and transient ischemic attacks (tia). hyperlipidemia: simvastatin-teva is indicated as an adjunct to diet to reduce elevated total-c ldl-c apo b and tg and to increase hdl-c in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (frederickson types iia and iib) simvastatin-teva therefore lowers the ldl-c/hdl-c and the total-c/hdl-c ratios.homozygous familial hypercholesterolemia: simvastatin-teva is also indicated as an adjunct to diet and other non-dietary measures in reducing elevated total cholesterol ldl-cholesterol and apolipoprotein b in patients with homozygous familial hypercholesterolemia when response to these

Իսրայել - եբրայերեն - Ministry of Health

teva israel ltd - simvastatin - טבליה - simvastatin 80 mg - simvastatin - simvastatin - coronary heart disease : in patients with coronary heart disease and hypercholesterolemia simvastatin-teva is indicated to: reduce the risk of total mortality by reducing coronary death reduce the risk of non-fatal myocardial infarction reduce the risk for undergoing myocardial revascularization procedures.reduce the risk of stroke and transient ischemic attacks (tia). hyperlipidemia: simvastatin-teva is indicated as an adjunct to diet to reduce elevated total-c ldl-c apo b and tg and to increase hdl-c in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (frederickson types iia and iib) simvastatin-teva therefore lowers the ldl-c/hdl-c and the total-c/hdl-c ratios. homozygous familial hypercholesterolemia: simvastatin-teva is also indicated as an adjunct to diet and other non-dietary measures in reducing elevated total cholesterol ldl-cholesterol and apolipoprotein b in patients with homozygous familial hypercholesterolemia when response to these measure